Company Insights

EVH customer relationships

Explore interactive graphBrowse insights index
EVH customer relationship map

Evolent Health (EVH) — Customer Relationships and Strategic Implications

Evolent Health operates as a business-to-business healthcare services firm that monetizes through multi-year platform and managed care contracts, charging fixed per-member-per-month fees and variable, usage-linked fees for specialty and administrative services while recognizing revenue on a gross basis as the principal provider. The business sells care-management, specialty solutions, and full administrative services to payers and risk-bearing providers across the United States, creating revenue tied to member volumes and premium flows. For deeper tracking of how these customer relationships affect valuation and operational risk, visit https://nullexposure.com/.

Why customers matter: concentrated, contractual, and U.S.-centric revenue

Evolent’s commercial model creates sticky, recurring cash flows when contracts are long-term and subscription-like, but it also concentrates risk with a small number of large partners. The company discloses that revenue is recognized in the United States and that its contracts are typically multi-year, paid on a per-member-per-month basis with variable components linked to members or premiums. These characteristics produce predictable revenue under stable enrollment but create sensitivity to partner renewals and plan enrollment swings. For a practical investor view of counterparties and contract dynamics, see https://nullexposure.com/.

Founding anchors and intellectual property relationships

University of Pittsburgh Medical Center (UPMC)

UPMC is a founding partner in Evolent’s creation and is referenced in regulatory filings as part of the company’s origins, reflecting a legacy development and technology relationship established at founding in 2011. According to Evolent’s 2024 Form 10‑K disclosure, UPMC was a co‑founder and licensed development partner in the company’s early IP and services agreements (FY2024 filing).

The Advisory Board Company

The Advisory Board Company partnered with Evolent at founding and contributed licensed intellectual property and advisory services used to structure Evolent’s initial care‑management offerings. The 2024 Form 10‑K cites an Amended and Restated Intellectual Property License and Development Services Agreement between Evolent and The Advisory Board Company, documenting that relationship (FY2024 filing).

Takeaway: These founding relationships created licensed IP and development agreements that underpin Evolent’s platform — a structural asset that supports product delivery and differentiates the company from pure software vendors.

Commercial payer and partner relationships — who drives revenue

Passport Health Plan

Evolent provided administrative services and transitioned approximately 470 of Passport’s employees into a partnership that began in 2016, a relationship that led to litigation noted in reporting. A Courier‑Journal article covering the dispute described Evolent’s provision of administrative services and employee transition tied to the deal (news report, 2019).

Privia Management Company, LLC

Privia acquired Evolent Care Partners Holding Company from Evolent, representing a corporate transaction that affects Evolent’s portfolio of managed‑care assets and the scope of partner relationships; Marketscreener documented the divestiture in FY2025 reporting (news report, FY2025).

Highmark (HMK)

Evolent announced a large oncology partnership with Highmark during its Q4 2025 earnings commentary, identifying Highmark as the counterparty for a material specialty care management engagement (Q4 2025 earnings call).

Blue Cross (BCBS)

Evolent referenced a Blue Cross partner in its Q4 2025 commentary as publishing data showing roughly a 40% reduction in hospitalizations and ER visits for patients using Evolent’s cancer navigation solution, illustrating product efficacy with a major commercial plan (Q4 2025 earnings call).

Humana Inc. (HUM)

Evolent partners with major national payers including Humana; public commentary and market coverage list Humana among prominent industry collaborations (news coverage, FY2024). The company’s filings also list Humana as one of the largest partners by revenue, underscoring its materiality to the business.

Takeaway: Evolent’s customer mix includes state/regional plans (Passport), national payers (Humana, Blue Cross), and provider‑aligned partnerships (Highmark), yielding a mix of administrative outsourcing, specialty programs, and joint product launches that drive both recurring revenue and episodic project fees.

Contracts, pricing mechanics, and company-level constraints

Evolent’s disclosures and contract excerpts collectively signal the following company-level operating characteristics:

  • Contracting posture: Predominantly multi‑year engagements with renewal risk concentrated among a handful of large partners. Evidence in filings describes recurring multi‑year platform and operations contracts.
  • Pricing mechanics: A blend of subscription-style fixed PMPM fees and usage/volume‑based variable fees tied to member counts or a percentage of premiums, creating both steady base revenue and variable upside/downside with enrollment changes.
  • Revenue recognition and role: Evolent states it is the principal for services it controls and therefore recognizes revenue on a gross basis; this indicates operational responsibility for service delivery rather than pure pass-through facilitation.
  • Geography and exposure: All revenue is recognized in the United States and most long‑lived assets are U.S.-based, concentrating regulatory, enrollment, and payer risk domestically.
  • Material concentration: The company discloses historical reliance on a limited number of partners for a substantial portion of revenue; in filings the four largest partners — including Humana — collectively represented a sizable share of consolidated revenue for 2024.

Bold risk point: Concentration among a few large partners creates outsized renewal and operational risk, despite high contractual stickiness.

Relationship-level summaries (concise)

  • University of Pittsburgh Medical Center — Founding co‑partner that contributed licensed IP and development services at Evolent’s founding; cited in the company’s 2024 Form 10‑K as part of its origin story and contractual history (FY2024 10‑K).
  • The Advisory Board Company — Early partner that licensed intellectual property to Evolent and supported development agreements; referenced in the 2024 Form 10‑K and incorporation documents (FY2024 10‑K).
  • Passport Health Plan — A 2016 partnership where Evolent provided administrative services and absorbed roughly 470 Passport employees, later subject to legal disputes reported in 2019 (Courier‑Journal news, 2019).
  • Privia Management Company, LLC — Acquired Evolent Care Partners Holding Company from Evolent, a divestiture that alters the company’s partner and asset footprint (Marketscreener report, FY2025).
  • Highmark (HMK) — Identified in Evolent’s Q4 2025 earnings call as the counterparty to a large, announced oncology partnership, reflecting continued expansion into specialty care collaborations (Q4 2025 earnings call).
  • Blue Cross (BCBS) — A Blue Cross partner published data, highlighted by Evolent in Q4 2025 remarks, showing a ~40% reduction in hospital and ER utilization for users of Evolent’s cancer navigation product (Q4 2025 earnings call).
  • Humana Inc. (HUM) — Listed in market coverage and filings as a prominent partner and one of the company’s largest revenue contributors, confirming Humana’s material role in Evolent’s commercial base (news coverage and 2024 filings).

What investors and operators should watch next

  • Contract renewal cadence and customer concentration: Monitor renewal outcomes, especially with Humana and other top partners, as a delayed or adverse renewal would materially affect revenue given disclosed concentration.
  • Product adoption vs. pricing mix: Track the balance between fixed PMPM revenue and variable premium‑linked fees to model revenue sensitivity to enrollment and utilization.
  • Operational integration risk: Divestitures such as the Privia transaction change Evolent’s service footprint and should be evaluated for near-term margin and cash implications.

For direct access to counterparty intelligence and structured relationship analysis, visit https://nullexposure.com/.

Conclusion and actionable guidance

Evolent operates a service‑centric, contract‑driven business with predictable base revenue and variable exposure through usage-based fees; the company’s value is tightly linked to a handful of large payer and provider relationships and to its licensed IP origins. Investors should treat upcoming renewals and the performance of newly announced specialty partnerships (e.g., Highmark oncology) as primary catalysts and risk levers. Operators and risk teams should prioritize contract governance, client retention programs, and visibility into per-member economics.

To review Evolent’s counterparties and contractual signals in one place, explore the platform at https://nullexposure.com/.